Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation
Lund, Sweden, June 1, 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-class treatment, Idefirix, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor. Idefirix is available for eligible highly sensitized patients starting today, June 1, 2023. Idefirix is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in Belgium.